Many of those who should get it, don't. And many of those who shouldn't, do. That's the story of a common screening test for osteoporosis, according to new research.

Some blind individuals use echoes from tongue or finger clicks to recognize objects in the distance, such echolocation can almost be a radar 'replacement' for vision. 

Recent research showed that echolocation in blind individuals is a full form of sensory substitution, and that blind echolocation experts recruit regions of the brain normally associated with visual perception when making echo-based assessments of objects.

Computer simulations have predicted a new phase of matter: atomically thin two-dimensional liquid.

Playing natural sounds such as flowing water in offices could boosts worker moods and improve cognitive abilities in addition to providing speech privacy, according to a new study.

An increasing number of modern open-plan offices employ sound masking systems that raise the background sound of a room so that speech is rendered unintelligible beyond a certain distance and distractions are less annoying. Sound masking systems are custom designed for each office space by consultants and are typically installed as speaker arrays discretely tucked away in the ceiling. For the past 40 years, the standard masking signal employed is random, steady-state electronic noise -- also known as "white noise."

Enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer's Disease Following Addition to Symptomatic Therapy), vTv's Phase 3 placebo controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of mild Alzheimer's disease has begun. Phase 3 begins following a Phase 2 trial that demonstrated positive results in slowing cognitive decline with 5 mg/day of azeliragon in patients with mild to moderate Alzheimer's Disease.

Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo.

As previously reported, at the 50 mg dose of tenapanor, the study met its primary efficacy endpoint of an increase in the complete spontaneous bowel movement (CSBM) responder rate. Most secondary endpoints, including abdominal pain and other abdominal and IBS-C symptoms, demonstrated clinically meaningful improvements.

Tenapanor was well-tolerated, and the safety results were consistent with those observed in previous tenapanor trials.